

Announcement No. 19/2008

To OMX Nordic Exchange Copenhagen and the press.

Copenhagen, 2 April 2008

Exiqon A/S issues new warrants to the company's supervisory board and to employees in a subsidiary

Following the annual general meeting today 2 April 2008 the supervisory board of Exiqon A/S has resolved to issue 71,388 warrants to the chairman of the supervisory board Thorleif Krarup, 29,991 warrants to the vice chairman of the supervisory board Erik Walldén, 29,991 warrants to member of the supervisory board Michael Nobel and 29,991 warrants to member of the supervisory board Per Wold-Olsen. Further, it was resolved to issue 384,530 warrants to certain employees in Exiqon A/S' American subsidiary Oncotech Inc. All warrants were issued in accordance with the authorization granted in article 3c of the articles of association, and in respect of the warrants issued to the supervisory board they were issued in accordance with the overall guidelines for incentive schemes for the supervisory board and executive board of Exiqon A/S as approved by the extraordinary general meeting on 31 January 2008.

The warrants issued entitle the warrant holders to subscribe for up to nom. DKK 545,891 shares of DKK 1.00 each in Exiqon A/S, and the supervisory board at the same time resolved to increase the Exiqon A/S' share capital accordingly.

The exercise price for the issued warrants is DKK 33,90 per warrant which corresponds to the average closing price of the Company's shares in the last five trading days up to and including 1 April 2008, plus 5% per year.

Of the warrants issued one thirty-sixth (1/36) hereof are vested as from the first day of the calendar month following the date of issuance of these warrants. Another one thirty-sixth (1/36) of these warrants are vested as from the first day of each new calendar month until all of these warrants have become vested. Unexercised warrants become null and void after expiry of the first exercise period following 36 months after allocation.

The resolution of the supervisory board has been included in article 3c4 of the company's articles of association.

Further, the supervisory board decided to appoint the Company's CFO Hans Henrik Chrois Christensen as a new member of the management board. The management board, hereafter, consists of CEO Lars Kongsbak og CFO Hans Henrik Chrois Christensen.

For additional information please contact

CEO Lars Kongsbak, tel. +45 4566 0888 or +45 4090 2101

CFO, Hans Henrik Chrois Christensen tel.+45 4565 0953 or +45 4090 2131

About Exiqon

Exiqon's corporate mission is to combine leading-edge scientific expertise in gene expression with our proprietary LNA™ technology. Exiqon's products, services and scientific staff enable life science researchers to make groundbreaking discoveries. Moreover, Exiqon is addressing the unmet need for a new approach to the diagnosis of cancer. Exiqon's products are based on patented technology (LNA™ or Locked Nucleic Acids) that facilitates very precise and sensitive



analysis of nucleic acids. Exiqon aims to expand the existing product offering for research use as well as to develop new proprietary molecular diagnostic products. Exiqon, through a number of recent initiatives, has positioned itself as a significant player in applying miRNA as the key biomarker in cancer diagnostics.

Disclaimer

Forward-looking statements: This announcement contains forward-looking statements regarding Exiqon's potential future development and financial performance and other statements which are not historical facts. Such statements are made on the basis of assumptions and expectations which, to the best of Exiqon's knowledge, are reasonable and well-founded at this time, but which may prove to be erroneous. Exiqon's operations are characterized by the fact that its actual results may deviate significantly from that described herein as anticipated, believed, estimated or expected.